| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 496.42 | 14.3% |
| Total Income | 506.32 | 14.1% |
| Expenditure | 425.57 | 9.5% |
| PBT | 80.75 | 32.0% |
| Net Profit | 60.45 | 31.5% |
| OPM | 24.36% | 2.83pp |
| NPM | 11.94% | 3.04pp |
| EPS | 2.90 | 31.6% |
Sai Life Sciences Reports 77% Revenue Growth YoY in Q1FY26, With Revenue at 496 Cr, EBITDA at 125 Cr, and Net Profit at 60 Cr
08 Aug 2025 · 8 Aug 2025, 09:43 am
Summary
Sai Life Sciences Limited, a Contract Research, Development and Manufacturing Organization (CRDMO), announced its financial results for the first quarter and Fiscal year 2026. The company reported a 77% YoY growth in revenue, which stood at 496 Cr for Q1FY26. EBITDA was 125 Cr, up by 303% from Q1FY25. The company also invested 134 Cr in capital expenditure during Q1FY26 and onboarded 253 scientists and technical staff.
Key Highlights
- 1
Revenue from Operations was 496 Cr for Q1FY26 compared to 280 Cr in Q1FY25, an increase of 77%
- 2
EBITDA stood at 125 Cr. for Q1FY26 compared to 31 Cr in Q1FY25, an increase of 305%
- 3
Invested 134 crore in capital expenditure during Q1FY26
- 4
Commenced commercial operations at Bidar Unit IV (PB-11 Phase II), adding ~91 KL capacity
- 5
Inaugurated Peptide Research Center at Hyderabad R&D campus
- 6
Inaugurated 10,300 sq. ft. Biology facility with multiple laboratories
- 7
Construction underway for new Medicinal Chemistry block with 200 fume hood capacity
- 8
Commencing work on building an additional 200 KL production capacity at Unit IV, Bidar
- 9
Onboarded 253 scientists and technical staff to support scaling
Management Comments
Mr. Krishna Kanumuri
Managing Director and CEO
We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. This momentum reflects the growing trust and deepening engagement we share with our global pharma clients’ relationships that continue to anchor us through macroeconomic uncertainty and broader industry cycles.
Mr. Siva Chittor
Director and Chief Financial Officer
We are pleased to report a robust performance for Q1FY26, marked by strong growth across our Discovery and CDMO businesses. Total revenue for the quarter stood at 496 Cr, up 77% YoY, led by 113% growth in our CDMO segment and a 38% rise in Discovery revenues.
Informational and educational content only. Not investment advice.